Elena Christofides, MD, is the chief executive officer of Endocrinology Associates, the scientific and medical advisor for Sparrow Pharmaceuticals, and a clinical associate professor at the Ohio University Heritage College of Osteopathic Medicine.

CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D

Interim data from the phase 2 CAPTAIN-T2D trial have indicated a substantial unmet need among patients with difficult-to-control 

, specifically in elevated post-dexamethasone suppression test (DST) cortisol.

Endocrine Society (ENDO) Annual Meeting 2026

 in Chicago, Illinois, by Elena Christofides, MD, the chief executive officer of Endocrinology Associates, scientific and medical advisor for Sparrow Pharmaceuticals, and a clinical associate professor at the Ohio University Heritage College of Osteopathic Medicine, this trial ultimately aims to evaluate clofutriben for the reduction of intracellular cortisol in several major tissues among these patients.

, Christofides discussed the rationale for the trial’s structure, highlighting the unmet need faced by many patients with subtle cortisol increases. As most clinicians are trained to view hypercortisolism primarily – and sometimes exclusively – as an indication of classic Cushing’s syndrome, patients with less pronounced elevations are often missed or undertreated.

“We need to reframe the conversation around what the consequences are of elevated cortisol, and when we should intervene,” Christofides told 

. “That’s the real struggle – we have been very dismissive as a general rule around the comorbidities associated with elevated cortisol, because it’s all too easy to blame societal changes, environmental changes, or personal changes, and so we end up gaslighting the patients about the disease process.”

Clofutriben is a selective inhibitor of human 11b-hydroxysteroid dehydrogenase type 1 (HSD-1), currently in development by Sparrow Pharmaceuticals to reduce intracellular cortisol in liver, adipose, muscle, and pancreas tissues, among others. Previous animal studies have indicated the drug’s efficacy in preventing corticosterone toxicities.

The CAPTAIN-T2D trial aims to assess the prevalence of elevated cortisol in patients with difficult-to-control T2D, as well as attempting to establish clofutriben’s dose-response relationship for HbA1c reduction in these patients. Christofides and colleagues plan to investigate roughly 1500 patients – of these, 332 have been screened via DST to date.

Difficult-to-control T2D was defined as HbA1c ≥7.5% despite ≥2 antidiabetic medications (ADMs), as well as the use of either ≥3 ADMs or ≥2 

, or the presence of a diabetes complication, osteoporosis, or prior Cushing syndrome diagnosis. Following screening, investigators expect to enter roughly 210 patients with post-DST cortisol >1.8 µg/dL into 24 weeks of randomized, placebo-controlled treatment to identify the appropriate dose for HbA1c reduction in a future phase 3 trial.

Of the 332 patients currently screened, 27.7% displayed post-DST cortisol levels >1.8 µg/dL. Analysis of demographic and clinical characteristics, including medications, T2D duration, and complications, as well as comorbidities and laboratory measures across post-DST cortisol categories is currently ongoing, according to Christofides and colleagues. In the meantime, the team has determined that, following their tracking of elevated post-DST cortisol in patients with difficult-to-control T2D, they have uncovered a significant unmet need in cardiometabolic disease. The full results of the study, including the response of HbA1c, body habitus, lipids, blood pressure, and other cardiometabolic risk factors to clofutriben, are expected to publish in Q4 2027.

“The data is clear historically that patients who still have persistent hypercortisolism and disrupted rhythm, even if their comorbidities are managed, their mortality is increased,” Christofides said. “So, yes, look for a solution that may be surgical for that patient, because that’s obviously going to be curative for that person, but in the meantime, do not ignore the fact that they’re metabolically compromised and marching towards a premature death, while you ignore that metabolic abnormality looking for a surgical solution.”

Editors’ Note: Christofides reports disclosures with Ascendis, Eli Lilly, Novo Nordisk, Recordati, Corcept, Crinetics, and others.

Christofides E, Buse J, Fonseca V, et al. Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes: Interim Results for CAPTAIN-T2D, a Phase 2 Trial of Clofutriben. Abstract presented at the Endocrine Society (ENDO) Annual Meeting 2026, Chicago, IL. June 13-15, 2026.

Buttgereit F, Everding A, Andreica I, et al. Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Ann Rheum Dis. 2026;85(5):921-931. 

Videos

Elena Christofides, MD, discusses the interim results of CAPTAIN-T2D, a trial that plans to evaluate clofutriben’s efficacy in these patients.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado.

VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities

New data from the Phase 3 VITESSE trial of the VIASKIN Peanut Patch (DBV Technologies) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 in Istanbul, Turkey, show that the epicutaneous immunotherapy device produced statistically significant efficacy versus placebo in children aged 4 to 7 years with 

and ≥ 1 additional atopic condition. Response rates at 12 months ranged from 46.8% to 48.3% across subgroups defined by concomitant asthma, additional food allergies, or atopic dermatitis, all closely tracking the overall responder rate of 46.6% in the patch arm compared with 14.9% for placebo.

The findings are particularly meaningful given how well the enrolled population mirrors patients seen in real-world allergy practice. In VITESSE, atopic comorbidities were highly prevalent: 61.8% of the 654 randomized participants had atopic dermatitis, 56.6% had ≥ 1 additional food allergy, and 35.8% had asthma. For David Fleischer, MD, director of allergy and immunology at Children's Hospital Colorado, the composition of the trial population was not surprising.

"Most of our patients with food allergy often have atopic dermatitis. Many of them have other food allergies… [or] asthma,” Fleischer said in an interview with 

“It’s very reassuring to show that the typical patient we're going to see in our clinic was seen in this trial and that patients with these atopic conditions did well.”

The risk difference between the patch and placebo arms was largest in the atopic dermatitis subgroup, at 34.0 percentage points (95% confidence interval [CI], 25.09 to 42.94; response rates: 47.2 vs 13.2%), compared with 33.2 points in the food allergy subgroup (95% CI, 23.50 to 42.83; response rates: 46.8% vs 13.6%) and 28.8 points in the asthma subgroup (95% CI, 15.79 to 41.76; response rates: 48.3% vs 19.6%). Fleischer said the signal in the atopic dermatitis group, while notable, was consistent with the broader understanding of skin-mediated immunologic responses.

“While we think that atopic dermatitis sets patients up for developing food allergy because they can become sensitized to the skin, the skin can actually desensitize patients, meaning [it] actually [does] what it's supposed to do here by increasing the threshold of the amount that patients can tolerate,” Fleischer said. He added that the data confirm the patch is safe to use in this population and that the localized skin reactions associated with its use are typically self-resolving or manageable with topical steroids.

A recurring theme in Fleischer's assessment was the practical advantages of epicutaneous delivery in a patient population that is already complex to manage. Unlike oral immunotherapy, the VIASKIN Peanut Patch does not require dose holds during illness or exercise restrictions, which Fleischer described as meaningful for families juggling concurrent atopic conditions.

"Throwing a peanut patch, a cutaneous immunotherapy, into your treatment regimen, along with treating your eczema… [or] asthma, is not going to add a significant burden onto what you're already managing," Fleischer said. “It's really an easy product that’s practical and easy to use."

He also acknowledged that patients need to be prepared for a longer timeline to response and that patients need to be patient with the product. Fleischer said that expectation-setting with families is part of appropriate counseling.

Looking ahead, Fleischer said the next steps include publication of the data and submission of a US Food & Drug Administration (FDA) application. DBV Technologies announced in late February that the company plans to submit a biologics license application (BLA) to the FDA this year.

 A separate safety study in children aged 1 to 3 years, requested by the FDA, is also underway. Fleischer said that data, once available, will support an application to extend the indication to that age group.

“Hopefully by next year, 1–7-year-olds will have the opportunity to be treated with a very safe, effective treatment that's very practical for families,” he said.

Editor’s note: Relevant disclosures for Fleischer include DBV Technologies, ARS Pharmaceuticals; UpToDate, Bryn Pharma, Aquestive Therapeutics, Nasus, and Genentech, and Grow Happy.

Jonathan. DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 | DBV Technologies. Dbv-technologies.com. Published June 8, 2026. Accessed June 15, 2026. 

https://dbv-technologies.com/press_releases/dbv-technologies-to-present-new-positive-data-from-vitesse-study-and-preview-recently-initiated-thrive-study-at-the-eaaci-congress-2026/

Fleischer D. VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD. HCPLive. March 23, 2026. Accessed June 15, 2026. 

https://www.hcplive.com/view/viaskin-peanut-patch-shows-strong-phase-3-vitesse-results-david-fleischer-md

Phase 3 VITESSE subgroup data show response rates of 46% to 48% in children with peanut allergy and concomitant asthma, atopic dermatitis, or food allergies, says David Fleischer, MD.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Experts introduce the 2026 AACE type 2 diabetes algorithm’s new classification pathway and frame misclassification—especially of adult-onset type 1 diabetes—as a central problem the update is designed to address.

Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm

In this segment, Susan Samson, MD, opens the discussion by situating the 2026 AACE Algorithm for the Management of Adults With Type 2 Diabetes within the broader need to move beyond a default diagnosis of type 2 diabetes. She explains that the new update includes a dedicated diabetes classification algorithm, a conceptual addition intended to stand alongside traditional glycemic management pathways. According to Samson, the key question embedded in this framework is deceptively simple but clinically powerful: “Are you sure the patient has type 2 diabetes?” This reframing sets the stage for a more deliberate diagnostic approach in adults who present with hyperglycemia.

Guillermo Umpierrez, MD, underscores the significance of this change by contrasting the 2026 version with the 2023 algorithm, which did not include a discrete classification pathway. He notes that the new algorithm is designed to remind clinicians to consider etiologies beyond type 2 diabetes at both initial diagnosis and over the course of established disease. The panel emphasizes that obesity, insulin resistance, and weight gain are highly prevalent in patients with type 2 diabetes, but these features can be misleading when applied uncritically to every adult with hyperglycemia. The algorithm is therefore intended to prompt a systematic review of clinical features that might suggest alternative diagnoses.

Samson then highlights literature showing that misclassification of adult-onset type 1 diabetes as type 2 diabetes is common and clinically consequential. She cites data from the UK “DARE” cohort, in which nearly 40% of adults older than 30 years who met criteria for type 1 diabetes were treated as if they had type 2 diabetes and did not receive insulin at diagnosis. She also notes that a substantial proportion of type 1 diabetes is diagnosed in adulthood, with more than one-third of patients receiving a diagnosis after age 30.

Together, Samson and Umpierrez frame the new classification algorithm as a response to this misclassification burden, intended to help clinicians reassess presumed type 2 diabetes when the clinical course is atypical.

Video Series

This episode breaks down the multi-layered biological mechanisms through which cortisol acts as a powerful catalyst for hyperglycemia by systematically increasing muscle insulin resistance, triggering the breakdown of fat cells and forcing the liver to overproduce glucose.

The Cortisol–Diabetes Connection

In the second episode of our insights series, 

Cortisol and Type 2 Diabetes: What Patients Need to Know,

 John Buse, M.D., Ph.D., addresses the complex question of whether cortisol is a direct cause of type 2 diabetes or a contributing factor. Buse explains that even with massive exposure to steroids — such as during high-dose chemotherapy for lymphoma or abrupt autoimmune disease onset — cortisol alone is generally not enough to cause diabetes in a completely normal or diabetes-resistant individual. Instead, it acts as a powerful catalyst in people who already carry an underlying, background risk for the disease. While a large portion of the population is fundamentally at risk because their bodies cannot secrete enough insulin to compensate for increased insulin resistance, individual sensitivity to steroids varies wildly; some individuals can gain significant weight and maintain normal glucose tolerance, while others might develop hyperglycemia from a quick steroid taper for something as simple as poison ivy.

The episode goes on to explore the multiple biological mechanisms through which cortisol contributes to high blood sugar. Buse breaks down how cortisol disrupts normal metabolism on several fronts: it increases insulin resistance specifically in the muscles to decrease glucose uptake, spikes hepatic glucose production in the liver and triggers lipolysis, which is the breakdown of fat cells. Furthermore, excess cortisol reduces direct insulin secretion and negatively impacts the production of incretin hormones. By systematically interfering with how these different organs and hormones process energy, cortisol builds a multi-layered path toward hyperglycemia.

Finally, Buse tackles the relationship between chronic stress, hypercortisolism and insulin resistance, noting that the relationship is far more intricate than most patients realize. While chronic stress is associated with elevated cortisol, Buse clarifies that the severe level of excess cortisol causing difficult-to-control type 2 diabetes involves a more complex bodily process than just daily lifestyle stress alone. Because cortisol receptors are active in every single cell in the body, excess levels can trigger a dozen or more disruptive mechanisms simultaneously. This widespread impact allows cortisol to interfere not only with glucose metabolism, but also with blood pressure regulation, vascular biology, and bone health, illustrating just how deeply intertwined hormonal balance is with a patient’s total cardiovascular and metabolic wellness.

Michelle Min, MD, MSCi, is an associate professor and serves as the director of Rheumatologic Dermatology at the UC Irvine School of Medicine.

2026 Society of Dermatology Physician Assistants (SDPA)

 editorial team spoke with Michelle Min, MD, MSCi, about the growing need for cross-specialty collaboration between dermatology and rheumatology clinicians during her session, “The Rheum-Derm Connection: Diagnostic and Therapeutic Pearls.”

Emerging therapies and ongoing phase 3 trials may significantly expand treatment options for patients with dermatomyositis, cutaneous lupus, and other rheumatologic skin diseases.

Dermatologists play a critical role in diagnosing autoimmune and connective tissue diseases, with clinical examination often providing insights beyond laboratory testing and biopsies.

Even when rheumatologists manage systemic disease, dermatologists can offer unique skin-directed treatments such as botulinum toxin for Raynaud phenomenon and hyaluronidase for scleroderma-associated microstomia.

Early recognition of rheum-derm conditions can be life-changing, as patients may initially present to dermatology with symptoms that mimic common disorders such as eczema or routine hair loss.

In this interview, Min highlighted the growing momentum in rheum-dermatology, pointing to emerging therapies for conditions such as dermatomyositis and cutaneous lupus. She noted that patients with skin manifestations of rheumatologic diseases historically have had limited 

-approved treatment options, but ongoing research and late-stage clinical development could significantly expand the treatment armamentarium.

Min also emphasized that dermatologists play a critical role in diagnosing autoimmune and connective tissue diseases, often identifying characteristic clinical findings before laboratory testing or biopsies provide definitive answers. The following Q&A interview highlights her responses to inquiries by 

 regarding the takeaways from this session at SDPA:

Are there any systemic agents you feel are important to highlight and that you hope clinicians are aware of, either recent or upcoming approvals?

Yeah, that's a great question. It's a really exciting time for room derm right now, because there are a lot of new treatments that are in phase 3. There's 1 that's even likely to get approved by the FDA this August for dermatomyositis. It's a TKY2, JAK1 inhibitor, brepocitinib. It'll probably be available on the market the first week of September, so we have a lot of exciting advancements coming for a long time. When it came to skin manifestations of rheumatologic diseases, we actually had nothing FDA-approved. So technically, we've had a hydroxychloroquine anti-malarial for systemic lupus. It's not actually, if you look at the package insert, approved for skin lupus, of course.

We do use it, and then IVIG got approved in 2021 for dermatomyositis, but before that we had nothing approved for dermatomyositis. So it's exciting because there's a lot of research, and I think this is changing. Another great example is we have anifrolumab that was also approved in the last few years for systemic lupus, but not cutaneous lupus. There are there's an ongoing phase 3 clinical trial right now specifically looking at cutaneous lupus, and I'm very hopeful that we'll get an FDA indication.

It's already a drug that we're using off-label to help our patients with skin lupus. We know there are many, many patients where the skin lupus is actually the only manifestation of their lupus, or they might have systemic lupus, but the systemic lupus is actually doing all right; it's the skin lupus that's not doing well. Again, as derms, as we have more medications available for us to prescribe. I think we need to be able to take back some of these patients, because no one's going to care about skin disease more than the patient, of course.

Were there any other notable clinical pearls that you wanted to highlight from your session at the SDPA meeting?

I really want to emphasize that the physical exam is so critical. Yes, biopsies can be helpful, additional lab tests can be helpful, but your clinical suspicion for a lot of these diseases trumps everything, and even for systemic diseases, again, derms can offer very unique treatments. A treatment that we'll talk about is botulinum toxin for Raynaud's phenomenon for severe systemic sclerosis patients. That's something that a rheumatologist is not going to be comfortable managing. Even as a [dermatology clinician], if you don't want to be the primary person managing systemic sclerosis, and that's understandable.

There are still treatments that you can offer as a dermatologist that a rheumatologist is not going to be able to. Another treatment that we'll be talking about is hyaluronidase injections around the mouth for scleroderma patients with oral microstomia. That's difficulty opening the mouth because the skin is so tight. Again, as derms, even if you're not the primary one prescribing a systemic medication that's outside of your comfort zone, being able to understand what we can offer that's unique from the rheumatologist is something that we're going to emphasize as well.

For any dermatologists, PAs, or NPs who are attending, would you point to a key takeaway you would like attendees to walk away from your talk with?

The one that I mentioned, that their physical exam is powerful. I think a lot of [dermatology clinicians] feel like a rheumatologist will be able to better differentiate some of these autoimmune diseases, because autoimmune diseases are primarily what they do. But you'd be surprised. And it shouldn't be the case. No one should understand skin diseases better than dermatologists. I also want to emphasize that rheumatologists are concerned about the patient as a whole.

I mean, we all are concerned about patients as a whole, but they're looking at lab values, how the heart and lungs are doing. Obviously, those are very important things, but there have been instances where a rheumatologist has reassured a patient with a rheumatoid condition, saying, ‘Hey, your labs look great. Yes, your skin disease, it's on your face, it's disfiguring, it's scarring, but you're not going to die.’ The patient obviously is very bothered by a disfiguring skin disease, and so again, as derms, skin is our baby; that's the organ that we're the most worried about. I think it's a mistake for us as dermatologists just to assume the rheumatologists are going to care about the skin disease or be as aggressive about skin disease as much as dermatologists would.

Were there any other notable elements of your session that you hope clinicians walk away with?

The other thing I want to emphasize is in dermatology, if a patient doesn't know their diagnosis, they may come to dermatology before they see rheumatology or primary care. If the primary problem is the skin, and a lot of times people come in thinking they have eczema but it's actually dermatomyositis, or they think that they have routine hair loss, but it's actually discoid lupus on the scalp.

You know, you never know what's going to land in your office, and I think it's really important for us to be equipped to be able to experience and be able to help make these diagnoses. [It’s also important] to make some of these rheum and derm diagnoses correctly early on. It can really be life-changing. We have a lot of power here to help patients, and we should remember that and utilize it.

Disclosures: Min had no relevant disclosures of note.

Min M. The Rheum-Derm Connection: Diagnostic and Therapeutic Pearls. Presented at SDPA Summer 2026. Jun 10-14, 2026.

Min M. Key Diagnostic and Therapeutic Pearls for Connective Tissue Disease, With Michelle Min, MD. HCPLive. June 14, 2026. 

https://www.hcplive.com/view/key-diagnostic-therapeutic-pearls-connective-tissue-disease-michelle-min-md

Articles

Cross-specialty collaboration between dermatology and rheumatology is increasingly essential as late-stage programs expand therapeutic options for dermatomyositis and cutaneous lupus, long areas with limited labeled treatments. Near-term regulatory activity includes a likely FDA approval of brepocitinib (TYK2/JAK1 inhibitor) for dermatomyositis, building on IVIG’s 2021 approval and broader lupus advances such as anifrolumab. Dermatologists’ pattern recognition and physical examination often drive earlier diagnosis than labs or biopsy, and dermatology-specific procedural interventions can materially improve morbidity in systemic sclerosis.

In her SDPA interview, Min discusses dermatology and rheumatology collaboration, exploring treatment options for connective tissue disease.

Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD

Elif Oral, MD, is a professor in the Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan.

Elif Oral, MD, discusses the clinical implications of the recent data emphasizing metreleptin’s anti-drug antibodies and their llack of impact on efficacy.

Dyslipidemia

Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity. 

Tirzepatide (Zepbound) Improves Kidney Transplant Eligibility in T2D and CKD With Severe Obesity

Elif Oral, MD, discusses her recent presentation at ENDO 2026 covering a phase 4 trial of the immunogenicity of metreleptin in this rare disease.

Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.


Type 1 Diabetes

Weight Loss, Not GLP-1 Therapy, Predicts Systolic Blood Pressure Change in Diabetes 

This SDPA interview highlights the connection between dermatology and rheumatology, noting diagnoses that can be challenging for rheumatologists.

Key Diagnostic and Therapeutic Pearls for Connective Tissue Disease, With Michelle Min, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dapagliflozin Reduces Insulin Requirements at Discharge After CABG in Patients With T2D

This SDPA Summer Conference interview with Lisa Swanson, MD, highlights several notable treatment options for molluscum and hemangiomas.

Tips on Treating Hemangiomas and Molluscum Contagiosum in Children, With Lisa Swanson, MD

Rosemarie Lajara, MD, FACE, is a staff physician at Southern Endocrinology and Diabetes Associatess 

At ENDO 2026, persistent symptoms in hypothyroidism may reflect non-thyroid causes, underscoring the need for broader clinical evaluation

Identifying Confounders in Persistent Hypothyroidism Symptoms, With Rosemarie Lajara, MD

At ENDO 2026, persistent fatigue and brain fog despite normal thyroid labs underscored the need for individualized care.


Looking Beyond TSH in Hypothyroidism Management, With Rosemarie Lajara, MD

Greater BMI reduction with semaglutide in adolescents with severe obesity was tied to improved triglycerides, TG/HDL ratio, and HbA1c

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Latest News

CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D

VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities

Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm

The Cortisol–Diabetes Connection

Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD